A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 518 participants.

Also called NCT05206084

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 518 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05206084
Other papers using this trial's data
  • Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II) Journal of the American College of Cardiology, 2026-04-28 DOI, PubMed 41670556

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05206084. Randomized; single masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2024-12-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
Acronym
IRONMAN-II
Intervention (Device)
Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Intervention (Device)
Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
Lead sponsor
Biotyx Medical (Shenzhen) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05206084
Content hash
152b5db96c5d3aacb4da0cd86183bcb01fac0cf7e4bac01719c6b517bf43ed8b